Roivant Sciences Ltd. filings document material events for a Nasdaq-listed Bermuda biopharmaceutical company with common shares registered under the ticker ROIV. The company’s recent Form 8-K disclosures cover quarterly financial results, preliminary liquidity information, share repurchases, Regulation FD updates and exhibits tied to clinical programs at subsidiaries such as Priovant Therapeutics.
Its filings also record material definitive agreements and amendments, including the Genevant Sciences settlement agreement involving lipid nanoparticle delivery technology, as well as shareholder voting results from the annual general meeting. Governance disclosures include director elections, auditor ratification and other proxy-related voting matters, while clinical exhibits describe programs such as brepocitinib in autoimmune and inflammatory diseases.
Form 144 notice reports a proposed sale of 138,602 common shares of Roivant Sciences Ltd. (ROIV) through Rockefeller Financial LLC on 10/08/2025 on NASDAQ, with an aggregate market value of $2,244,797.15. The shares were acquired the same day through option exercises granted on 03/26/2020 and 11/20/2017, totaling 138,602 shares and paid by wire. The filer also discloses multiple recent sales by the same account over the past three months, including large transactions on 09/19/2025 (683,818 shares, gross proceeds $10,220,412.21) and several other sales totaling over $38M in gross proceeds across listed dates. The form includes the filers representation about absence of undisclosed material adverse information and standard signature attestation.
Roivant Sciences Ltd. (ROIV) filed a Form 144 disclosing a proposed sale of 355,161 common shares by a covered person through Rockefeller Financial LLC on 10/07/2025, with an aggregate market value of $5,734,289.35 and 682,881,743 shares outstanding. The filing shows those shares were acquired on 10/07/2025 by exercise of stock options granted on 03/26/2020, 11/20/2017, and 04/20/2022, with 67,171, 107,131, and 180,859 shares from each grant respectively, and payment by wire.
The form also lists multiple sales by Eric Venker in the prior three months totaling over 1.99 million shares across trades between 07/21/2025 and 10/06/2025 with gross proceeds exceeding $31M (sum of reported proceeds). The filer certifies no undisclosed material adverse information and follows the Rule 144 disclosure requirements.
Roivant Sciences Ltd. insider filing reports a proposed sale under Rule 144 of 171,396 common shares with an aggregate market value of $2,800,364.71 to be sold on 10/06/2025 through Rockefeller Financial LLC on NASDAQ. The shares were acquired the same day via option exercises with grant dates in 2017, 2020, and 2022, and payment was wired on 10/06/2025. The filing also discloses multiple recent sales by the same account during the past three months, including large transactions on 07/21/2025, 08/20/2025, 09/19/2025, 09/22/2025, and 09/23/2025, with individual gross proceeds shown per sale.
Roivant Sciences Ltd. filed a Form S-3ASR prospectus dated October 3, 2025 establishing a base shelf and a Sales Agreement to offer common shares and other securities on a continuous or delayed basis. The prospectus expressly permits the issuance of Common Shares up to an aggregate offering price of $400.0 million pursuant to a Sales Agreement dated September 19, 2022 with TD Securities (USA) LLC (successor to Cowen and Company, LLC); as of filing $0 of that $400.0 million had been sold. The company states it has an active share repurchase program and may or may not use this registration statement.
The document discloses capital structure data as of June 30, 2025: 682,229,832 Common Shares issued and outstanding, 138,728,031 shares issuable upon exercise of options (weighted average exercise price $8.70), and 72,009,936 shares issuable upon settlement of RSUs/PRSU/CVARs. Audited financial statements for year ended March 31, 2025 and internal control effectiveness are reported by Ernst & Young LLP. The prospectus highlights extensive risk factors related to biopharmaceutical development, capital needs, regulatory approval, intellectual property, controlling shareholders, dilution and litigation risk, and states Common Shares trade on Nasdaq under ROIV.
Richard Pulik, Chief Financial Officer of Roivant Sciences Ltd. (ROIV) reported the disposition of 2,341 common shares on 09/28/2025 at a price of $15.17 per share. The Form 4 states this disposition represents a net settlement of previously granted restricted stock units (RSUs) to satisfy tax withholding obligations upon vesting. After the transaction, the reporting person beneficially owns 389,508 shares. The filing was signed on behalf of Mr. Pulik by an attorney-in-fact on 09/30/2025. All information is limited to the transaction details disclosed in the Form 4.
Roivant Sciences insider sale and post-transaction holding. The company's CFO and director, Richard Pulik, reported a disposition of 2,129 common shares on 09/20/2025 at a price of $15.04 per share. The filing states this disposition represents a "net settlement" to satisfy tax withholding related to previously granted RSUs. After the transaction Pulik beneficially owns 391,849 shares.
Roivant Sciences Ltd. (ROIV) insider filing shows Eric Venker, President & Immunovant CEO, reporting option awards and multiple share sales. The Form 4 discloses grants of stock options exercisable at $3.85 covering 1,562,374 options in total (1,000,000 on 09/19/2025; 462,374 and 100,000 on 09/22/2025) with an April 19, 2032 expiration and vesting tied to a 04/20/2022 commencement schedule. The filing also reports open-market sales totaling 1,711,000 common shares across 09/19–09/23/2025 at weighted-average prices disclosed in ranges (examples: $14.95, $14.99, $15.01, $14.83), some effected pursuant to a Rule 10b5-1 trading plan adopted June 25, 2024. Post-transactions, reported beneficial ownership figures for common stock and underlying options are shown on the form.
Roivant Sciences Ltd. (ROIV) filed a Rule 144 notice disclosing a proposed sale of 611,079 shares of common stock, scheduled approximately 09/23/2025 through Charles Schwab & Co. The filing lists an aggregate market value of $9,129,520.26 and reports 682,881,743 shares outstanding. The shares were acquired as equity compensation on 01/20/2023 for services rendered. The filer also reported three recent sales by Eric Venker totaling 1,200,000 shares between 07/21/2025 and 09/19/2025 with combined gross proceeds shown. The notice includes the standard representation that the seller has no undisclosed material adverse information.
Roivant Sciences Ltd. (ROIV) filed a Form 144 notifying a proposed sale of 316,182 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $4,741,054.24, scheduled approximately for 09/22/2025. The shares were reported acquired the same day via a stock option exercise and paid for in cash. The filing also discloses prior sales by Eric Venker totaling 883,818 shares across July–September 2025 with combined gross proceeds of $12,644,412.21. The notice includes the sellers representation there is no undisclosed material adverse information.
Roivant Sciences Ltd. (ROIV) insider notice under Rule 144: This Form 144 reports a proposed sale of 100,000 common shares by a person for whose account the securities are to be sold, using Rockefeller Financial LLC as broker on 09/22/2025. The filing states an aggregate market value of $1,501,338.85 for the shares and notes there are 682,881,743 shares outstanding.
The shares were acquired the same day through an options exercise (grant date 04/20/2022) from Roivant Sciences Ltd., with payment by wire. The filer also discloses two prior sales in the past three months: 100,000 shares sold on 08/20/2025 (gross proceeds $1,172,120.12) and 100,000 shares sold on 07/21/2025 (gross proceeds $1,151,941.91).